Starting immunoglobulin for infection prevention in hematology
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with a blood condition and low antibody levels.
- You have not had or are not scheduled for a stem cell transplant from a donor.
- You are not already taking daily antibiotics to prevent bacterial infections.
- You have not received immunoglobulin in the last 3 months.
- You do not have an allergy to immunoglobulin or a known IgA deficiency with anti-IgA antibodies.
- You are not pregnant, breastfeeding, or have severe kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.